In angioplasty procedures, a balloon is fed through a catheter and used to prop open an artery that has become narrowed or blocked. In cases where stenting is appropriate, a stent mounted on a balloon is inserted and inflation of the balloon expands the stent against the blocked artery wall to hold the vessel open. The balloon is then deflated and the catheter is withdrawn. Stent treatment of arteries holds them open and improves blood flow to the heart. In cases where post-dilatation is needed, a high-pressure balloon is inflated inside a stent to help better place the stent against the vessel wall.
Researchers from North Carolina State University have developed an exosome-coated stent with a "smart-release" trigger that could both prevent reopened blood vessels from narrowing and deliver regenerative stem cell-derived therapy to blood-starved, or ischemic, tissue.
ST segment-elevation myocardial infarction (STEMI) is a particularly severe type of heart attack associated with a high risk of mortality or long-term disability.
A surgical procedure advanced and studied by vascular neurosurgeons at Cedars-Sinai dramatically reduced the rate of recurrent strokes among patients with atherosclerotic disease, a new study shows.
A recent study by University of Alberta cardiologists at the Canadian VIGOUR Centre shows that a particular group of patients with stable ischemic heart disease have better outcomes with percutaneous coronary intervention (also called angioplasty with stent) or coronary artery bypass surgery and medication, versus conservative management with medication alone.
Percutaneous coronary intervention (PCI), commonly known as angioplasty with a stent, opens clogged arteries and saves lives. Despite its benefit in treating atherosclerosis that causes coronary artery disease, this common minimally-invasive procedure still poses severe complications for some patients.
Approximately 1.5 million heart attacks and strokes occur every year in men and women in the U.S. Sex and age play a large part in who experiences a heart attack, the methods used to treat these heart attacks, and the eventual post hospital outcomes of the people who experience heart attacks.
Women face a 20% increased risk of developing heart failure or dying within five years after their first severe heart attack compared with men.
Heart attacks, strokes and other cardiovascular incidents can be cut by 20 to 40 per cent through use of a polypill which combines three blood pressure medications and a lipid lowering medication taken alone or with aspirin.
A one-month treatment of dual anti-platelet therapy is safe and as effective as a longer duration of therapy at preventing cardiac events in patients one year after stent placement, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
The use of the more potent antiplatelet medication ticagrelor was not superior to clopidogrel in the reduction of the rate of heart attack or severe complications among people undergoing an elective procedure to open a blocked artery, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary heart attack, stroke, bypass surgery or death, among elderly people who had survived a recent heart attack, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
Adults from underrepresented racial groups who have acute heart blockages and cardiac arrests received fewer early interventions, had longer hospital stays and higher death rates than their white counterparts, according to preliminary research to be presented at the American Heart Association's Resuscitation Science Symposium 2020.
The Ellipsys Vascular Access System reduces the time before patients with kidney failure can start lifesaving dialysis treatments, while requiring fewer secondary procedures, according to a new study led by interventional radiologist Jeffrey Hull, M.D., of Richmond Vascular Center.
An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by 34 per cent the number of serious adverse events following balloon angioplasty, a treatment for the most common form of heart disease.
A new study shows significant benefits of the Ellipsys Vascular Access System in easily and safely creating durable vascular access for end-stage renal disease (ESRD) patients who require hemodialysis.
Researchers at the University of Illinois at Chicago have developed a new drug that prevents blood clots without causing an increased risk of bleeding, a common side effect of all antiplatelet medications currently available.
Women's risk of falling ill with cardiovascular disease, and dying from it, is lower than that of men of the same age, irrespective of where in the world they live.
Pairing a blood-thinning drug with aspirin daily for patients who have an angioplasty with a stent can contribute to better health outcomes, including lower risk of death, than aspirin alone, according to a recent study by cardiologists at the University of Alberta and Mazankowski Alberta Heart Institute.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Is personalized medicine cost-effective? University of Alabama at Birmingham researcher Nita Limdi, Pharm.D., Ph.D., and colleagues across the United States have answered that question for one medical treatment.